TSL.L Regulatory News (TSL)

15 Dec 2006 16:55

Tissue Science Laboratories PLC15 December 2006 15 December 2006 Tissue Science Laboratories PLC ("TSL" or "the Company") Tissue Science Laboratories PLC (AIM:TSL), the medical technology companyspecialising in tissue repair, today announces that it is applying for theadmission to trading on AIM for a total of 550,768 ordinary shares of 10p each(the "Ordinary Shares") that have been issued between June 2003 and January 2006as set out below. At various dates between 11 June 2003 and 26 April 2006, 268,866 Ordinary Shareswere issued pursuant to the Tissue Science Laboratories plc Management ShareOption Scheme, at various dates between 20 September 2004 and 4 January 2006128,135 Ordinary Shares were issued pursuant to the Tissue Science Laboratoriesplc Sharesave Option Scheme and on 21 September 2004, 153,767 shares were issuedin respect of share warrants held by West Equity Bridge Finance Limited. Trading in the Ordinary Shares, which rank pari passu in all respects with theexisting ordinary shares, is expected to commence on or around 20 December 2006. -Ends- Enquiries: TSL plc Tel: 01252 369 603Martin Hunt, Chief ExecutiveDavid Jennings, Finance Director Hogarth Partnership Limited Tel: 020 7645 3965Sarah Richardson Background on TSL Founded in 1995, with headquarters in Aldershot, Hampshire, TSL is a medicaltechnology company specialising in tissue repair and replacement with aproprietary sheet product, derived from porcine dermis, called Permacol(R). TSLhas launched successfully different formulations of the product and built adevelopment pipeline that addresses the large and fast growing surgical implantmarket. The Company floated in November 2001 and is listed on the AlternativeInvestment Market (LSE: TSL). TSL has a family of products based on the same core technology. Each producthas been adapted, with unique properties, to make it suitable for use indifferent applications, including urology/gynaecology, complex and recurrenthernia repair, shoulder rotator cuff repair and head and face repair andreconstruction. The Company has signed distribution agreements with CR Bard Inc(urology/gynaecology - worldwide), Zimmer Inc (orthopaedic - worldwide) andPorex Surgical Inc (head & face-US and Canada). Further variations of the sheetand injectable forms of Permacol(R) are being developed. This information is provided by RNS The company news service from the London Stock Exchange